© 2004 by Oxford University Press
© 2004 Oxford University Press
COMMENTARY |
Cancer Stem Cells: Are We Missing the Target?
Affiliation of authors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
Correspondence to: Richard J. Jones, MD, Bunting-Blaustein Cancer Research Building, 1650 Orleans St., Rm. 207, Baltimore, MD 21231 (e-mail: rjjones@jhmi.edu)
| The first 150 words of the full text of this article appear below. |
 |
INTRODUCTION |
|---|
Most conventional anticancer agents are nonselective cellular poisons with broad activities against most dividing cells, regardless of whether they are malignant or not; any preferential effects of these agents on cancer cells usually reflect their relatively high rates of cell division. The widely acclaimed success of imatinib mesylate (also known as STI571 or Gleevec, and herein referred to as imatinib) in chronic myeloid leukemia (CML) highlights the enormous possibilities that the development of drugs directed against cancer-specific targets has for improving cancer treatment. Targeted anticancer agents have the potential to favorably influence patient survival by decreasing toxicity and improving disease control. However, recent laboratory and clinical data raise questions about whether new anticancer agents will effectively target relevant subsets of cancer cells. These issues have implications for interpreting results of clinical studies with targeted therapies as well as for the future development of new anticancer treatments.
|
IMATINIB IN CHRONIC MYELOID LEUKEMIA: A MODEL OF TARGETED THERAPY |
|---|
The cytogenetic hallmark of
|
RESISTANCE TO IMATINIB |
|---|
|
CANCER STEM CELLS AND TARGETED THERAPY |
|---|
|
DRUG DEVELOPMENT FOR CANCER: ARE WE OFF TARGET? |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Q. Shu, K. K. Wong, J. M. Su, A. M. Adesina, L. T. Yu, Y. T. M. Tsang, B. C. Antalffy, P. Baxter, L. Perlaky, J. Yang, et al. Direct Orthotopic Transplantation of Fresh Surgical Specimen Preserves CD133+ Tumor Cells in Clinically Relevant Mouse Models of Medulloblastoma and Glioma Stem Cells, June 1, 2008; 26(6): 1414 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Li, M. T. Lewis, J. Huang, C. Gutierrez, C. K. Osborne, M.-F. Wu, S. G. Hilsenbeck, A. Pavlick, X. Zhang, G. C. Chamness, et al. Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy J Natl Cancer Inst, May 7, 2008; 100(9): 672 - 679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhou, J. Wulfkuhle, H. Zhang, P. Gu, Y. Yang, J. Deng, J. B. Margolick, L. A. Liotta, E. Petricoin III, and Y. Zhang Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance PNAS, October 9, 2007; 104(41): 16158 - 16163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Senan and E. F. Smit Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy Oncologist, April 1, 2007; 12(4): 465 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Narazaki and G. Tosato Tumor cell populations differ in angiogenic activity: a model system for spontaneous angiogenic switch can tell us why. J Natl Cancer Inst, March 1, 2006; 98(5): 294 - 295. [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Wicha, S. Liu, and G. Dontu Cancer Stem Cells: An Old Idea--A Paradigm Shift Cancer Res., February 15, 2006; 66(4): 1883 - 1890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Biagiotti, M. D'Amico, I. Marzi, P. Di Gennaro, A. Arcangeli, E. Wanke, and M. Olivotto Cell Renewing in Neuroblastoma: Electrophysiological and Immunocytochemical Characterization of Stem Cells and Derivatives Stem Cells, February 1, 2006; 24(2): 443 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Huff, W. Matsui, B. D. Smith, and R. J. Jones The paradox of response and survival in cancer therapeutics Blood, January 15, 2006; 107(2): 431 - 434. [Abstract] [Full Text] [PDF]
|
|